David Gerber, M.D. is a faculty member within the Hematology Oncology Division at UT Southwestern Medical Center. Within the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern, he serves as Associate Director for Clinical Research and as Co-leader of the Experimental Therapeutics Program. Dr. Gerber graduated cum laude from Yale University in New Haven, Connecticut, and his medical degree was obtained through Cornell University Medical College, New York, New York. His internship and residency in Internal Medicine were completed at UT Southwestern Medical Center in Dallas, Texas with his fellowship in medical oncology at Johns Hopkins University School of Medicine in Baltimore, Maryland. Dr. Gerber is board certified in Internal Medicine and Medical Oncology.
Dr. Gerber is genuinely interested in Lung cancer and is highly active in his research pertaining to Lung cancer, including clinical trials. His research has generated over 130 publications that he has authored or co-authored, including articles, abstracts, book chapters, books reviews and invited manuscripts. His studies have contributed to invitations to lecture both nationally and internationally.
Dr. Gerber not only serves on a number of committees at UT Southwestern Medical Center, but he is also an active participant for the Lung Cancer Education Committee of the American Society of Clinical Oncology (ASCO) and the Career Development Committee with the International Association for the Study of Lung Cancer (IASLC). He has served on the editorial board of the Journal of Clinical Oncology. He has served on grant review committees for ASCO and the Department of Defense. Dr. Gerber holds memberships to several professional societies, and has been honored with numerous awards, including Best Doctors in Dallas, D Magazine, since 2011.
- Medical School
- Weill Cornell Graduate School of Medical Science (2000)
- UT Southwestern Medical Center (2004), Internal Medicine
- Johns Hopkins Hospital (2007), Medical Oncology
- Lung cancer, clinical and translational research
- Oncology outcomes research
- Randomized phase 3 study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer.
- Gerber DE, Horn L, Boyer M, Sanborn R, Natale R, Palmero R, Bidoli P, Bondarenko I, Germonpre P, Ghizdavescu D, Kotsakis A, Lena H, Losonczy G, Park K, Su WC, Tang M, Lai J, Kallinteris NL, Shan JS, Reck M, Spigel DR Ann. Oncol. 2018 May
- Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.
- Gerber DE, Socinski MA, Neal JW, Wakelee HA, Shirai K, Sequist LV, Rosovsky RP, Lilenbaum RC, Bastos BR, Huang C, Johnson ML, Hesketh PJ, Subramaniam DS, Dietrich MF, Chai F, Wang Y, Kazakin J, Schwartz B, Schiller JH, Brahmer JR, Kelly RJ Lung Cancer 2018 Mar 117 44-49
- How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis.
- Khan SA, Pruitt SL, Xuan L, Makris U, Gerber DE Lung Cancer 2018 Jan 115 97-102
- Cancer Center Clinic and Research Team Perceptions of Identity and Interactions.
- Reimer T, Lee SJC, Garcia S, Gill M, Duncan T, Williams EL, Gerber DE J Oncol Pract 2017 Oct JOP2017024349
- Institutional Scientific Review of Cancer Clinical Research Protocols: A Unique Requirement That Affects Activation Timelines.
- Ning N, Yan J, Dietrich MF, Xie XJ, Gerber DE J Oncol Pract 2017 Oct JOP2017024299
- Thoracic oncology clinical trial eligibility criteria and requirements continue to increase in number and complexity.
- Garcia S, Bisen A, Yan J, Xie XJ, Ramalingam S, Schiller JH, Johnson DH, Gerber DE J Thorac Oncol 2017 Jul
- Prevalence of Autoimmune Disease Among Patients With Lung Cancer: Implications for Immunotherapy Treatment Options.
- Khan SA, Pruitt SL, Xuan L, Gerber DE JAMA Oncol 2016 Jun
- Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer.
- Gerber DE, Boothman DA, Fattah FJ, Dong Y, Zhu H, Skelton RA, Priddy LL, Vo P, Dowell JE, Sarode V, Leff R, Meek C, Xie Y, Schiller JH Lung Cancer 2015 Oct
- Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual.
- Laccetti AL, Pruitt SL, Xuan L, Halm EA, Gerber DE J. Natl. Cancer Inst. 2015 Apr 107 4
- Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts.
- Gerber DE, Hao G, Watkins L, Stafford JH, Anderson J, Holbein B, Öz OK, Mathews D, Thorpe PE, Hassan G, Kumar A, Brekken RA, Sun X Am J Nucl Med Mol Imaging 2015 5 5 493-503
Targeted Therapies for Non-Small Cell Lung Cancer
David E. Gerber (2011). Oxford University Press
Apar K. Ganti, David E. Gerber (Ed.) (2014). Oxford University Press
Honors & Awards
- Castle Connolly Top Doctors
- D Magazine Best Doctors in Dallas
- National Cancer Institute Clinical Investigator Team Leadership Award
- International Association for the Study of Lung Cancer (2008)
- American Society of Clinical Oncology (2004)